Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 4
Submit an article Journal homepage
209
Views
15
CrossRef citations to date
0
Altmetric
Letters to the Editor

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

Amer M. ZeidanSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; Correspondence[email protected]
,
Rong WangCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;
,
Cary P. GrossCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Steven D. GoreSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Scott F. HuntingtonSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Thomas PrebetSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;
,
Gregory A. AbelDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
,
Amy J. DavidoffCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA
&
Xiaomei MaCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;
show all
Pages 982-985 | Received 24 May 2016, Accepted 13 Jul 2016, Published online: 25 Aug 2016
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

The authors acknowledge the efforts of the Applied Research Program, National Cancer Institute; the Office of Research, Development and Information, Information Management Services, Inc.; and the SEER Program tumor registries in the creation of the SEER database.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1214954.

AMZ, SDG, TP, XM, and SH have consulted for Celgene the manufacturer for azacitidine.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.